Detroit Free Press

Diorasis Therapeutics and Northway Biotech Announce Partnership for the Development and Manufacturing of AAV Gene Therapy for Glaucoma

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial

Life Biosciences will test its gene therapy designed to partially reset a cell’s age and potentially reverse vision loss in patients with glaucoma and NAION.
EurekAlert!

Gene therapy for glaucoma

Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye. Patients often rely on daily eye drops to ...
The Indianapolis Star

Diorasis Therapeutics and Northway Biotech Announce Partnership for the Development and Manufacturing of AAV Gene Therapy for Glaucoma

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...
Morningstar

Diorasis Therapeutics and Northway Biotech Announce Partnership for the Development and Manufacturing of AAV Gene Therapy for Glaucoma

Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...